GRAIL, Inc. (GRAL) vs Veracyte, Inc. (VCYT)
GRAIL, Inc. and Veracyte, Inc. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $5.5B against $3.9B — 1.4× the size. GRAIL, Inc. has negative trailing earnings, so its P/E is not meaningful; Veracyte, Inc. trades at 31.5×. GRAIL, Inc. grew revenue faster over the last twelve months: 23.1% against 17.3%. Veracyte, Inc. has the higher net margin (20.4% vs −237.0%) and the higher return on invested capital (7.32% vs −20.8%). Across the 16 metrics below, Veracyte, Inc. leads on 13 and GRAIL, Inc. on 3.
Valuation
Profitability
| Metric | GRAL | VCYT | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | (31.31%) | 71.71% | 50.89% |
| Operating margin | (338.40%) | 18.82% | (8.57%) |
| Net margin | (236.95%) | 20.37% | (6.37%) |
| Free cash flow margin | (179.21%) | 29.54% | 0.00% |
| Return on equity | (16.12%) | 8.77% | (2.92%) |
| Return on assets | (14.12%) | 8.09% | (6.71%) |
| Return on invested capital | (20.79%) | 7.32% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack